Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
- PMID: 12646019
- DOI: 10.1021/jm0204183
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
Abstract
To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a number of different basic and weakly basic analogues were designed and synthesized. 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (12b or SU11248) has been found to show the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rbeta tyrosine kinase at biochemical and cellular levels, solubility, protein binding, and bioavailability. 12b is currently in phase I clinical trials for the treatment of cancers.
Similar articles
-
Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.J Med Chem. 2000 Jul 13;43(14):2655-63. doi: 10.1021/jm9906116. J Med Chem. 2000. PMID: 10893303
-
Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.J Pharmacol Exp Ther. 2003 Nov;307(2):476-80. doi: 10.1124/jpet.103.052530. Epub 2003 Sep 9. J Pharmacol Exp Ther. 2003. PMID: 12966161
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.Clin Cancer Res. 2003 Jan;9(1):327-37. Clin Cancer Res. 2003. PMID: 12538485
-
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.Anticancer Drug Des. 2000 Feb;15(1):29-41. Anticancer Drug Des. 2000. PMID: 10888034 Review.
-
[Recent advances in the study of pharmacological activities and solid-phase synthesis of indoles and their analogues].Yao Xue Xue Bao. 2006 Aug;41(8):694-701. Yao Xue Xue Bao. 2006. PMID: 17039771 Review. Chinese. No abstract available.
Cited by
-
Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.J Pharm Biomed Anal. 2010 Mar 11;51(4):958-64. doi: 10.1016/j.jpba.2009.10.006. Epub 2009 Oct 12. J Pharm Biomed Anal. 2010. PMID: 19896317 Free PMC article.
-
CRISPR-mediated knockout of VEGFR2/KDR inhibits cell growth in a squamous thyroid cancer cell line.FEBS Open Bio. 2022 May;12(5):993-1005. doi: 10.1002/2211-5463.13399. Epub 2022 Apr 8. FEBS Open Bio. 2022. PMID: 35313079 Free PMC article.
-
Drug repurposing for new, efficient, broad spectrum antivirals.Virus Res. 2019 Apr 15;264:22-31. doi: 10.1016/j.virusres.2019.02.011. Epub 2019 Feb 19. Virus Res. 2019. PMID: 30794895 Free PMC article. Review.
-
Exploring the Antiangiogenic Potential of Solomonamide A Bioactive Precursors: In Vitro and in Vivo Evidences of the Inhibitory Activity of Solo F-OH During Angiogenesis.Mar Drugs. 2019 Apr 15;17(4):228. doi: 10.3390/md17040228. Mar Drugs. 2019. PMID: 30991727 Free PMC article.
-
In silico studies of a novel scaffold of benzoxazole derivatives as anticancer agents by 3D-QSAR, molecular docking and molecular dynamics simulations.RSC Adv. 2023 May 15;13(22):14808-14824. doi: 10.1039/d3ra01316b. eCollection 2023 May 15. RSC Adv. 2023. PMID: 37197188 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases